Guided Therapeutics Shipping Largest Order to Date of LuViva® Advanced Cervical Scan Single-Patient-Use Disposables

23,000 Cervical Guides to Turkish distributor

NORCROSS, Ga.–(BUSINESS WIRE)–Guided Therapeutics, Inc. (OTCQB: GTHPD), the maker of a rapid and
painless testing platform based on its patented biophotonic technology,
announced today that the company is shipping its largest ever order of
single-use disposable Cervical Guides for use with the LuViva® Advanced
Cervical Scan. The order of approximately 23,000 disposables is shipping
to the company’s distributor for Turkey.

“This order represents the single largest order for disposables and
nearly doubles the number of Cervical Guides sold to Turkey to date,”
said Gene Cartwright, CEO and president of Guided Therapeutics, Inc.
“This order of disposables is for our new, improved design which reduces
waste, shipping and storage costs, making them better for our customers
and better for the environment.”

With the current order, the Company has sold 33 LuViva devices and
approximately 48,000 disposable Cervical Guides.

Worldwide, the market for cervical cancer screening and diagnostics, as
currently practiced using cytology (Pap test) for primary screening, is
estimated at $6 billion and is projected to grow to almost $9 billion by
2020. Including the developed countries, there are about 2.6 billion
women aged 15 years and older who are at risk of developing cervical
cancer worldwide.

Internationally, the company has regulatory approval to sell LuViva in
Europe upon receipt of our Edition 3CE Mark in January 2014. LuViva has
marketing approval from Health Canada, COFEPRIS in Mexico, Ministry of
Health in Kenya and the Singapore Health Sciences Authority.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which may result in eliminating costly, painful and
unnecessary additional testing. LuViva is intended for use with women
who have undergone initial screening and are called back for follow up
with a colposcopy examination, which in many cases, involves taking a
biopsy of the cervix. It has also been used in clinical studies in
Turkey and Nigeria as a means to screen women for cervical cancer where
the availability of infrastructure necessary for Pap and HPV testing is
restricted. The device is used in conjunction with the LuViva®
Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHPD) is the maker of a rapid and
painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular
level. The Company’s first product is the LuViva® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical trial,
with women at risk for cervical disease, the technology was able to
detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use in the U.S. LuViva, the wave logo and “Early
detection, better outcomes” are registered trademarks owned by Guided
Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of commercialization of products, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the sufficiency of capital raised in prior financings and the
ability to realize their expected benefits, the uncertainty of future
capital to develop products or continue as a going concern, the
uncertainty of regulatory approval of products, and the dependence on
licensed intellectual property, as well as those that are more fully
described from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2015
and subsequent filings.

Contacts

Investor and Media Relations Contact:
IRTH Communications
Robert
Haag, 866-976-4784
Managing Director
gthp@irthcommunications.com
or
Guided
Therapeutics
Bill Wells, 770-242-8723

Recibe gratis las noticias más importantes y más leídas diariamente en tu email

Este sitio está protegido por reCAPTCHA y Google Política de privacidad y Se aplican las Condiciones de servicio.

¡Muchas gracias!

Más sobre este tema
Contenido Patrocinado
Enlaces patrocinados por Outbrain